Clovis Oncology Inc. (NASDAQ:CLVS) was downgraded by investment analysts at Vetr from a “hold” rating to a “sell” rating in a report issued on Tuesday. They currently have a $33.59 price target on the biopharmaceutical company’s stock. Vetr‘s price objective points to a potential downside of 8.70% from the company’s current price.

A number of other research firms also recently issued reports on CLVS. SunTrust Banks Inc. boosted their target price on shares of Clovis Oncology from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, September 23rd. Zacks Investment Research downgraded shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, October 4th. Janney Montgomery Scott downgraded shares of Clovis Oncology from a “buy” rating to a “neutral” rating and boosted their target price for the company from $35.00 to $36.00 in a research report on Wednesday, September 21st. Stifel Nicolaus boosted their target price on shares of Clovis Oncology from $30.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, September 21st. Finally, Credit Suisse Group AG upgraded shares of Clovis Oncology from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $19.00 to $41.00 in a research report on Wednesday, September 21st. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company’s stock. Clovis Oncology currently has a consensus rating of “Hold” and an average price target of $35.97.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology (NASDAQ:CLVS) opened at 36.79 on Tuesday. The stock’s 50 day moving average price is $32.33 and its 200-day moving average price is $22.52. Clovis Oncology has a 12 month low of $11.57 and a 12 month high of $40.29. The stock’s market cap is $1.42 billion.

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.95) by $0.25. During the same quarter last year, the company earned ($2.62) EPS. Equities analysts expect that Clovis Oncology will post ($8.97) EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in CLVS. Alps Advisors Inc. boosted its stake in Clovis Oncology by 25.1% in the second quarter. Alps Advisors Inc. now owns 53,924 shares of the biopharmaceutical company’s stock worth $740,000 after buying an additional 10,828 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in Clovis Oncology during the second quarter worth approximately $154,000. State Board of Administration of Florida Retirement System boosted its stake in Clovis Oncology by 8.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 22,819 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 1,693 shares in the last quarter. Boxer Capital LLC bought a new stake in Clovis Oncology during the second quarter worth approximately $6,174,000. Finally, Quantitative Systematic Strategies LLC bought a new stake in Clovis Oncology during the second quarter worth approximately $751,000.

COPYRIGHT VIOLATION NOTICE: “Clovis Oncology Inc. (CLVS) Rating Lowered to Sell at Vetr Inc.” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of international copyright and trademark laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/11/24/clovis-oncology-inc-clvs-rating-lowered-to-sell-at-vetr-inc.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

5 Day Chart for NASDAQ:CLVS

Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.